Welcome to our dedicated page for Senti Biosciences news (Ticker: SNTI), a resource for investors and traders seeking the latest updates and insights on Senti Biosciences stock.
Senti Biosciences, Inc. (Nasdaq: SNTI) is a pioneering biotechnology company focused on developing next-generation cell and gene therapies. The company leverages its proprietary Gene Circuit platform to engineer adaptive therapies for treating complex diseases, with a strong focus on oncology. Senti Bio's core technology harnesses synthetic biology to create precision gene circuits that can enhance the efficacy and safety of cellular therapeutics.
Founded by a team of engineers, scientists, and entrepreneurs, Senti Biosciences has rapidly advanced its research and development through strategic partnerships and significant investments. The company's innovative approach utilizes allogeneic chimeric antigen receptor natural killer (CAR-NK) cells integrated with gene circuits to address challenging diseases. Senti Bio’s primary product candidates include SENTI-202 for hematologic malignancies like Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS), and SENTI-301A for the treatment of hepatocellular carcinoma (HCC).
- SENTI-202 employs Logic Gated CAR-NK cells designed to selectively target and eliminate cancer cells expressing CD33 and/or FLT3 antigens while sparing healthy bone marrow cells. The company received clearance from the U.S. FDA for its Investigational New Drug (IND) application and plans to initiate a Phase 1 clinical trial in 2024.
- SENTI-301A is designed for the treatment of HCC and is currently being developed in collaboration with Celest Therapeutics in China.
In addition to its primary pipeline, Senti Bio is actively exploring the potential of its Gene Circuit technology in other therapeutic areas and modalities, including partnerships with Spark Therapeutics and BlueRock Therapeutics. The company is committed to advancing its clinical programs and demonstrating the transformative potential of Gene Circuits in precision medicine.
Recent achievements include the establishment of a manufacturing partnership with GeneFab to support clinical-scale production and streamline operations to focus on key clinical programs. Senti Bio’s financial results reflect ongoing investments in research and development, with strategic efforts aimed at extending its cash runway and ensuring the successful advancement of its therapeutic candidates.
Senti Biosciences stays at the forefront of biotechnology innovation, dedicated to developing superior treatments for patients facing incurable diseases. Stay updated with Senti Bio’s latest developments and progress through their website and social media channels.
FAQ
What is the current stock price of Senti Biosciences (SNTI)?
What is the market cap of Senti Biosciences (SNTI)?
What is Senti Biosciences, Inc.?
What are Gene Circuits?
What are Senti Bio's main product candidates?
What is SENTI-202?
What is the status of SENTI-202?
Who are Senti Bio's partners?
What is the focus of SENTI-301A?
How is Senti Bio advancing its manufacturing capabilities?
Where can I find the latest news about Senti Biosciences?
What recent milestones has Senti Bio achieved?
